

Fig. S1. (A) Flow chart of the study cohort. (B) Effectiveness of upadacitinib treatment represented by oSCORAD over time in TREATgermany and definition of time frames. In this analysis patients are included that had a documented start visit for upadacitinib (n=97, black dots). Since the initiation of therapy does not have to have taken place exactly at the time of the visit, the black dots scatter around the origin. 76 of these patients had at least one follow-up visit (FUV) on upadacitinib (n=76, yellow triangles). To facilitate comparison with upadacitinib approval studies two time frames were defined in addition: after 3 months (n=43) and after 6 months (n=35) of upadacitinib therapy (grey areas). Most, but not all, of the patients had their 2nd FUV (blue rectangles) in the 2nd time frame.

